Greg Zante
2021
In 2021, Greg Zante earned a total compensation of $1.3M as Chief Financial Officer at Viking Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $136,000 |
|---|---|
| Option Awards | $318,261 |
| Salary | $400,000 |
| Stock Awards | $491,069 |
| Total | $1,345,330 |
Zante received $491.1K in stock awards, accounting for 37% of the total pay in 2021.
Zante also received $136K in non-equity incentive plan, $318.3K in option awards and $400K in salary.
Rankings
In 2021, Greg Zante's compensation ranked 7,685th out of 12,406 executives tracked by ExecPay. In other words, Zante earned more than 38.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,685 out of 12,406 | 38th |
Division Manufacturing | 3,385 out of 5,494 | 38th |
Major group Chemicals And Allied Products | 1,498 out of 2,369 | 37th |
Industry group Drugs | 1,332 out of 2,090 | 36th |
Industry Pharmaceutical Preparations | 981 out of 1,537 | 36th |
Source: SEC filing on April 7, 2022.
Zante's colleagues
We found two more compensation records of executives who worked with Greg Zante at Viking Therapeutics in 2021.